WHAT IS TAP?
TAP is LLS’ Mission-driven, strategic venture philanthropy initiative that seeks to accelerate the development of innovative blood cancer therapeutics and change the standard of care. TAP collaborates with biotech companies to support the development of novel platforms, first-in-class assets addressing unmet medical needs, emerging patient populations and even rare blood cancers.
Since establishment in 2007, TAP has invested >$100 million in biotech companies supporting over 50 therapies.
Since 2017, four TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA) or included in the National Comprehensive Cancer Network (NCCN) Guidelines:
- CPX-351 (Vyxeos®), first approved treatment (an innovative reformulation of two chemotherapies) for patients with certain types of high-risk acute myeloid leukemia (AML)
- Axicabtagene ciloleucel (Yescarta®), first CAR T-cell immunotherapy approved for patients with non-Hodgkin lymphoma (NHL) and transformed follicular lymphoma (tFL)
- Tagraxofusp-erzs (Elzonris®), first approved therapy for children and adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Duvelisib (Copiktra®), first dual inhibitor of PI3K-delta and gamma pathways included in NCCN Guidelines for patients with all subtypes of peripheral T-cell lymphoma (PTCL)
Currently, there are over 20 active clinical studies with TAP-supported therapies, including several registration-enabling clinical studies in blood cancer that could lead to more FDA approvals.
LLS leverages its over 70-year commitment to cures for blood cancers and has funded over 4000 projects since its inception, amounting to $1.6 billion of support toward disease control and cures. LLS knowledge and know-how in blood cancer drug development is unparalleled, underscored by LLS support for most of the new blood cancer therapies approved in the past 20 years.
To learn more about TAP: https://www.lls.org/tap
To learn more about LLS-supported Research: https://www.lls.org/lls-funded-research
